TG Therapeutics Third Quarter Conference Call - TG THERAPEUTICS INC

Explicit Guidance:

• FY2026 Revenue: Raised full-year global revenue guidance to $1 billion (previously implied lower) and U.S. pre-MV net product revenue guidance to $915–$920 million (up from $890–$920 million range) for 2026.
• Q4 2026 Performance: Expects a strong fourth quarter with projected U.S. pre-MV revenue exceeding $260 million, establishing the U.S. business at a $1 billion+ annualized run rate.
• FY2026 Expenses: Full-year R&D and SG&A (excluding stock-based compensation) expected to remain in the $450–$500 million range, inclusive of manufacturing startup costs.
• Cash & Capital Allocation: Maintained disciplined capital allocation; previously repurchased $100 million ($300 million total) in Q3 2026; no new guidance on future buyback timing or volume, but committed to balancing investment with shareholder returns.

Business-Segment Outlook:

• BrionV IV (U.S. Market): Targeting mid-2027 for potential FDA approval of a simplified single-dose initiation regimen (combining day 1 and 15 doses); anticipates this will drive demand growth in H2 2027 and beyond, with commercial impact beginning late 2027.
• BrionV Subcutaneous (SubQ): Phase 3 study fully enrolled; top-line data expected year-end 2026 or early 2027; targeting a 2028 commercial launch with an auto-injector device. Management views this as additive to IV, not a replacement, with a goal to more than double peak sales opportunity by accessing the "stealth" administration market (35% of new starts).
• Patient Demographics & Mix: Shift toward treatment-naive patients (currently 40% of new starts vs. 25% at launch) and adoption by younger women (18–40 years). "Wearing-off" data suggests patients switching from competitors experience reduced symptoms.
• Hospital Segment: Expecting sustained growth with September/October 2026 recording strongest hospital months since launch; building a durable recurring revenue base as patients return every six months.
• New Indications: Advancing BrionV into generalized myasthenia gravis (Phase 2) and treatment-resistant schizophrenia (Phase 2) to create value beyond relapsing MS.

Market and Competitive Outlook:

• Anti-CD20 Landscape: Believes "not all anti-CD20 therapies are the same"; data from Enhance/Enable reinforces differentiation. Aims to become the most prescribed anti-CD20 therapy among new MS treatment starts.
• BTK Inhibitors: Views BTK class as primarily competing in the oral category (approx. 30–35% of market) and expects them to fall short of CD20s in high-efficacy efficacy/safety profiles (e.g., dosing frequency, relapse reduction).
• Pricing & Net Price: Gross-to-net currently averaging ~65%; confident in sustainability without needing deeper discounts, utilizing price increases to offset payer mix/contracting pressures. No pricing changes expected with the combined IV initiation dose.
• Competitive Positioning: Strong momentum in switching patients from competitors (e.g., Ocrelizumab); 1/3 of new starts are switchers.

Macro / Industry Outlook:

• Policy Impact (340B): Minimal expected impact on BrionV IV revenue from 340B policy changes (affecting ~5% of business, primarily Medicare patients at 340B hospitals).
• Supply Chain: Manufacturing capacity for SubQ secondary source manufacturing and pre-MV production ramping up in H2 2026 to support 2028 launch.
• Financial Strength: Reaching $1B annual revenue milestone (less than 4 years post-launch) provides financial foundation for long-term R&D investments and M&A potential.

Strategic Initiatives:

• Dosing Innovation (Enhanced): Regulatory submission ongoing for single-dose IV initiation; potential label update mid-2027.
• SubQ Launch Preparation: Auto-injector device confirmed for 2028 launch; CMC readiness built into timeline.
• Clinical Pipeline Expansion:
  • Azra Cell (Allogeneic CAR-T): First clinical results in progressive MS show safety and potential efficacy; early data shows 90% of evaluable patients stable/improved EDSS at Day 90.
  • Long-term Data: 7-year Ultimate trial data shows 0.018 annualized relapse rate and 88% freedom from disability progression.
• Commercial Infrastructure: Investing in AI-enabled tools and data analytics to improve field targeting; expanding DTC initiatives to drive prescription lift.
• Capital Return: Continued share repurchases (average price < $34/share total) while funding growth.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: SubQ and simplified IV initiation approvals are "potential" and subject to FDA review (top-line data not yet final for SubQ).
• Competitive Actions: Competitors' transition efforts (IV to SubQ) and potential pricing pressure; BTK inhibitors evolving in the oral space.
• Clinical Outcomes: CAR-T (Azra Cell) data is early-stage; long-term efficacy and safety in progressive MS unknown.
• Execution Risk: Implementation of simplified dosing regimen requires center-level adoption and training; potential delays in 2028 SubQ launch if CMC or review issues arise.
• Macro Headwinds: Payer mix shifts and government discounts impacting net pricing.

Management Tone on the Future:

• Confidence Level: High. Describes progress as "remarkable" and "compelling." CEO Mike Weiss states, "I believe we're still early in the stage of what TG can become."
• Strategic Vision: Views BrionV as a "starting line" for a value creation engine; confident in the "operating leverage" of launching SubQ with existing infrastructure.
• Discipline: Emphasizes "disciplined with capital" and "thoughtful investments."
• Guidance Changes: Raised revenue guidance twice (Global to $1B, U.S. to $915–$920M) based on Q4 acceleration and strong Q3 trends.
• Differentiation: Strongly believes clinical evidence + patient experience will drive adoption ("When clinical evidence meets personal experience, adoption follows").

Miscellaneous:

• Safety Signals: 7-year data shows no new safety signals; SubQ injections showed only Grade 1 local/systemic reactions.
• Real-World Evidence: ENABLE study (1,000+ patients) shows 99% relapse-free status and lower infusion-related reaction rates than registrational trials.
• Indirect Comparisons: Published 5-year analysis suggests BrionV has 44% lower risk of disability progression vs. Ocrelizumab and 49% vs. Opdivo (Ocrevus).